162 related articles for article (PubMed ID: 37658563)
21. Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms.
Klöppel G; La Rosa S
Virchows Arch; 2018 Mar; 472(3):341-349. PubMed ID: 29134440
[TBL] [Abstract][Full Text] [Related]
22. Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms.
Corsello A; Di Filippo L; Massironi S; Sileo F; Dolcetta Capuzzo A; Gemma M; Carlucci C; Cusini C; Colombo B; Dallatomasina A; Franchi GM; Corti A; Manzoni MF
PLoS One; 2018; 13(5):e0196858. PubMed ID: 29723285
[TBL] [Abstract][Full Text] [Related]
23. Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.
Panzuto F; Merola E; Pavel ME; Rinke A; Kump P; Partelli S; Rinzivillo M; Rodriguez-Laval V; Pape UF; Lipp R; Gress T; Wiedenmann B; Falconi M; Delle Fave G
Oncologist; 2017 Apr; 22(4):409-415. PubMed ID: 28232598
[TBL] [Abstract][Full Text] [Related]
24. Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms.
Alexandraki KI; Karapanagioti A; Karoumpalis I; Boutzios G; Kaltsas GA
Biomed Res Int; 2017; 2017():9856140. PubMed ID: 29349087
[TBL] [Abstract][Full Text] [Related]
25. State of the Art in Endoscopic Therapy for the Management of Gastroenteropancreatic Neuroendocrine Tumors.
Papaefthymiou A; Laskaratos FM; Koffas A; Manolakis A; Gkolfakis P; Coda S; Sodergren M; Suzuki N; Toumpanakis C
Curr Treat Options Oncol; 2022 Jul; 23(7):1014-1034. PubMed ID: 35511346
[TBL] [Abstract][Full Text] [Related]
26. Clinico-morphological analysis of the neuroendocrine neoplasms of the gastroenteropancreatic system.
Delektorskaya VV; Kozlov NA; Chemeris GY
Klin Lab Diagn; 2013 Oct; (10):48-50, 10-3. PubMed ID: 24640093
[TBL] [Abstract][Full Text] [Related]
27. Clinical Syndromes Related to Gastrointestinal Neuroendocrine Neoplasms.
Boutzios G; Kaltsas G
Front Horm Res; 2015; 44():40-57. PubMed ID: 26303703
[TBL] [Abstract][Full Text] [Related]
28. Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs).
Effraimidis G; Knigge U; Rossing M; Oturai P; Rasmussen ÅK; Feldt-Rasmussen U
Semin Cancer Biol; 2022 Feb; 79():141-162. PubMed ID: 33905872
[TBL] [Abstract][Full Text] [Related]
29. Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot.
Fernandez CJ; Agarwal M; Pottakkat B; Haroon NN; George AS; Pappachan JM
World J Gastrointest Surg; 2021 Mar; 13(3):231-255. PubMed ID: 33796213
[TBL] [Abstract][Full Text] [Related]
30. Aberrant Expression of Long Non Coding RNA HOTAIR and De-Regulation of the Paralogous 13 HOX Genes Are Strongly Associated with Aggressive Behavior of Gastro-Entero-Pancreatic Neuroendocrine Tumors.
Di Mauro A; Scognamiglio G; Aquino G; Cerrone M; Liguori G; Clemente O; Di Bonito M; Cantile M; Botti G; Tafuto S; Tatangelo F
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34208964
[TBL] [Abstract][Full Text] [Related]
31. [Inherited tumor syndromes of gastroenteropancreatic and thoracic neuroendocrine neoplasms].
Couvelard A; Scoazec JY
Ann Pathol; 2020 Apr; 40(2):120-133. PubMed ID: 32035641
[TBL] [Abstract][Full Text] [Related]
32. Biomarkers in gastroenteropancreatic neuroendocrine neoplasms.
Jacoba IM; Weber HC
Curr Opin Endocrinol Diabetes Obes; 2023 Jun; 30(3):175-180. PubMed ID: 36895178
[TBL] [Abstract][Full Text] [Related]
33. Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas.
Patel N; Barbieri A; Gibson J
Surg Pathol Clin; 2019 Dec; 12(4):1021-1044. PubMed ID: 31672292
[TBL] [Abstract][Full Text] [Related]
34. [Neuroendocrine neoplasms : Two families with distinct features unified in one classification (German version)].
Klöppel G
Pathologe; 2019 May; 40(3):211-219. PubMed ID: 30969346
[TBL] [Abstract][Full Text] [Related]
35. Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study.
Zhang X; Ma L; Bao H; Zhang J; Wang Z; Gong P
BMC Endocr Disord; 2014 Jul; 14():54. PubMed ID: 25001493
[TBL] [Abstract][Full Text] [Related]
36. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.
Cavalcanti E; Armentano R; Valentini AM; Chieppa M; Caruso ML
Cell Death Dis; 2017 Aug; 8(8):e3004. PubMed ID: 28837143
[TBL] [Abstract][Full Text] [Related]
37. The Role of the Acute Octreotide Suppression Test in Detecting Patients with Neuroendocrine Neoplasms.
Kruljac I; Vičić I; Blaslov K; Kolak Z; Benković M; Kust D; Ladika Davidović B; Tometić G; Penavić I; Dabelić N; Vazdar L; Pavić T; Vrkljan M
Neuroendocrinology; 2018; 107(3):284-291. PubMed ID: 30114698
[TBL] [Abstract][Full Text] [Related]
38. Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based study.
Poleé IN; Hermans BCM; van der Zwan JM; Bouwense SAW; Dercksen MW; Eskens FALM; Havekes B; Hofland J; Kerkhofs TMA; Klümpen HJ; Latten-Jansen LM; Speel EM; Verburg FA; Walenkamp AME; Geurts SME; de Vos-Geelen J
Eur J Cancer; 2022 Sep; 172():252-263. PubMed ID: 35803176
[TBL] [Abstract][Full Text] [Related]
39. Secondary malignancy in patients with sporadic neuroendocrine neoplasia.
Krausch M; Raffel A; Anlauf M; Schott M; Lehwald N; Krieg A; Kröpil F; Cupisti K; Knoefel WT
Endocrine; 2013 Oct; 44(2):510-6. PubMed ID: 23494366
[TBL] [Abstract][Full Text] [Related]
40. Gastrointestinal neuroendocrine neoplasms (GI-NENs): hot topics in morphological, functional, and prognostic imaging.
Danti G; Flammia F; Matteuzzi B; Cozzi D; Berti V; Grazzini G; Pradella S; Recchia L; Brunese L; Miele V
Radiol Med; 2021 Dec; 126(12):1497-1507. PubMed ID: 34427861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]